Deutsche Bank AG Takes $11.54 Million Position in Xenon Pharmaceuticals Inc. $XENE

Deutsche Bank AG purchased a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 191,126 shares of the biopharmaceutical company's stock, valued at approximately $11,536,000. Deutsche Bank AG owned approximately 0.20% of Xenon Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its holdings in Xenon Pharmaceuticals by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 396,138 shares of the biopharmaceutical company's stock worth $23,035,000 after purchasing an additional 8,980 shares during the last quarter. Siren L.L.C. boosted its stake in shares of Xenon Pharmaceuticals by 62.2% during the 1st quarter. Siren L.L.C. now owns 1,318,564 shares of the biopharmaceutical company's stock valued at $76,674,000 after buying an additional 505,803 shares during the last quarter. Jennison Associates LLC grew its position in shares of Xenon Pharmaceuticals by 13.8% during the fourth quarter. Jennison Associates LLC now owns 1,292,055 shares of the biopharmaceutical company's stock worth $57,910,000 after buying an additional 156,820 shares in the last quarter. NEXTBio Capital Management LP acquired a new stake in shares of Xenon Pharmaceuticals during the fourth quarter worth approximately $8,234,000. Finally, Nicholas Investment Partners LP increased its stake in shares of Xenon Pharmaceuticals by 104.0% in the fourth quarter. Nicholas Investment Partners LP now owns 242,989 shares of the biopharmaceutical company's stock worth $10,891,000 after buying an additional 123,891 shares during the last quarter. Hedge funds and other institutional investors own 95.45% of the company's stock.

Insider Buying and Selling at Xenon Pharmaceuticals

In related news, Director Gillian Cannon sold 1,190 shares of the firm's stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the sale, the director owned 1,455 shares of the company's stock, valued at approximately $77,318.70. This trade represents a 44.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Gary Patou sold 1,322 shares of the business's stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the transaction, the director owned 24,896 shares of the company's stock, valued at $1,322,973.44. This represents a 5.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 12,512 shares of company stock worth $774,088 over the last ninety days. Company insiders own 2.91% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on XENE. Needham & Company LLC cut their price target on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a "buy" rating on the stock in a report on Friday, May 8th. Royal Bank Of Canada decreased their price objective on shares of Xenon Pharmaceuticals from $82.00 to $81.00 and set an "outperform" rating for the company in a report on Friday, August 7th. JPMorgan Chase & Co. boosted their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 27th. HC Wainwright restated a "buy" rating and issued a $74.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday, August 10th. Finally, Wall Street Zen raised shares of Xenon Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 1st. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $77.13.

Xenon Pharmaceuticals Price Performance

Shares of XENE opened at $60.77 on Friday. The business's fifty day moving average price is $62.32 and its 200 day moving average price is $55.69. Xenon Pharmaceuticals Inc. has a 12-month low of $35.60 and a 12-month high of $72.66. The stock has a market capitalization of $5.87 billion, a PE ratio of -12.82 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.05. During the same quarter in the prior year, the business posted ($1.07) EPS. As a group, research analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.73 earnings per share for the current fiscal year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source